Table 2.
Comparison of the characteristics of patients with and without VTE
| Overall population n = 428 | VTE group during follow-upa n = 64 | Non-VTE group during follow-upa n = 364 | P value | |
|---|---|---|---|---|
| Median age, range years | 50 (18–98) | 49 (22–81) | 50 (18–98) | 0.9698 |
| Gender, male n (%) | 209 (49%) | 34 (53%) | 175 (48%) | 0.4562 |
| Type of lymphoma: DLBCL | 241 (56%) | 45 (70%) | 196 (54%) | 0.0143 |
| Advanced diseaseb | 218 (51%) | 38 (59%) | 180 (49%) | 0.1430 |
| Constitutional symptoms | 258 (60%) | 23 (36%) | 41 (64%) | 0.5025 |
| Bulky disease | 45 (11%) | 17 (26%) | 28 (8%) | < 0.0001 |
| Poor prognostic diseasec | 178 (42%) | 34 (53%) | 144 (40%) | 0.0423 |
| High KRSd | 64 (15%) | 11 (17%) | 53 (15%) | 0.5868 |
| Death | 56 (13%) | 17 (27%) | 39 (11%) | 0.0005 |
P < 0.05: statistically significant
aThe percentages are related to the numbers presented in the first column of the same line
bAdvanced disease: stage according to Lugano IV
cIPI, International Prognostic Index ≥ 3; IPS, International Prognostic Score ≥ 3
dAccording to the Khorana Risk Score (KRS) for VTE risk assessment